- Home
- LUNG vs LXEO Comparison
LUNG vs LXEO Comparison
Compare LUNG & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- LXEO
- Stock Information
- Founded
- LUNG 1995
- LXEO 2017
- Country
- LUNG United States
- LXEO United States
- Employees
- LUNG N/A
- LXEO N/A
- Industry
- LUNG Industrial Specialties
- LXEO
- Sector
- LUNG Health Care
- LXEO
- Exchange
- LUNG Nasdaq
- LXEO Nasdaq
- Market Cap
- LUNG 251.5M
- LXEO 252.4M
- IPO Year
- LUNG 2020
- LXEO 2023
- Fundamental
- Price
- LUNG $6.23
- LXEO $6.14
- Analyst Decision
- LUNG Buy
- LXEO Strong Buy
- Analyst Count
- LUNG 6
- LXEO 5
- Target Price
- LUNG $11.92
- LXEO $23.80
- AVG Volume (30 Days)
- LUNG 252.9K
- LXEO 274.8K
- Earning Date
- LUNG 02-19-2025
- LXEO 12-31-2024
- Dividend Yield
- LUNG N/A
- LXEO N/A
- EPS Growth
- LUNG N/A
- LXEO N/A
- EPS
- LUNG N/A
- LXEO N/A
- Revenue
- LUNG $79,302,000.00
- LXEO N/A
- Revenue This Year
- LUNG $22.26
- LXEO N/A
- Revenue Next Year
- LUNG $18.72
- LXEO N/A
- P/E Ratio
- LUNG N/A
- LXEO N/A
- Revenue Growth
- LUNG 22.34
- LXEO N/A
- 52 Week Low
- LUNG $5.46
- LXEO $5.77
- 52 Week High
- LUNG $14.84
- LXEO $22.33
- Technical
- Relative Strength Index (RSI)
- LUNG 41.37
- LXEO 35.77
- Support Level
- LUNG $5.72
- LXEO $6.78
- Resistance Level
- LUNG $6.28
- LXEO $7.40
- Average True Range (ATR)
- LUNG 0.40
- LXEO 0.66
- MACD
- LUNG -0.03
- LXEO -0.13
- Stochastic Oscillator
- LUNG 19.85
- LXEO 1.34
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.